Curative resection of gallbladder cancer with liver invasion and hepatic metastasis after chemotherapy with gemcitabine plus S-1: report of a case

World Journal of Surgical Oncology

Hirokazu Noshiro¹  Kenji Kitahara¹  Atsushi Miyoshi¹  Takao Ide¹  Hiroki Koga¹  Hiroaki Nakamura¹  Yasushi Ide³  Keita Kai²  Jun Nakamura¹  Takashi Okumura¹ 

[1] Department of Surgery, Saga University Faculty of Medicine, Nabeshima 5-1-1, Saga, 849-8501, Japan;Department of Pathology and Microbiology, Saga University Faculty of Medicine, Nabeshima 5-1-1, Saga, 849-8501, Japan;Oda Hospital, Ohaza Takatsuhara 4360, Kashima City, Saga 849-1932, Japan

关键词: S-1;    liver metastasis;    gemcitabine;    gallbladder cancer;    chemotherapy;   

Others  :  1147538
DOI  :  10.1186/1477-7819-12-326

 received in 2014-04-19, accepted in 2014-10-20,  发布年份 2014

【 摘 要 】

A 62-year-old woman diagnosed with gallbladder cancer exhibiting broad liver invasion and metastasis to Couinaud’s hepatic segments 4 and 8 (S4 and S8) consulted her regular doctor. Owing to the presence of liver metastases, she received treatment with gemcitabine plus S-1. After four cycles of chemotherapy, the size of the main lesion dramatically decreased and the two liver metastases disappeared. After six cycles of chemotherapy, the patient was referred to our hospital for surgical treatment. Upon admission, there was no evidence of any distant metastasis, based on a detailed radiological examination. Therefore, we performed cholecystectomy and central bisegmentectomy of the liver after obtaining the patient’s informed consent. Pathological examination demonstrated viable cancer cells with granuloma formation and calcification in the gallbladder, as well as regenerative changes without viable cancer cells in S4 and S8 of the liver. Gemcitabine plus S-1 was again administered as postoperative adjuvant chemotherapy. One and a half years after the surgery, there were no signs of recurrence. In patients selected according to their response to chemotherapy, surgical treatment might therefore be effective against gallbladder cancer with metastasis.

【 授权许可】

   
2014 Okumura et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Hezel AF, Zhu AX: Systemic therapy for biliary tract cancers. Oncologist 2008, 13:415-423.
• [2]Miyakawa S, Ishihara S, Horiguchi A, Takada T, Miyazaki M, Nagakawa T: Biliary tract cancer treatment: 5,584 results from the biliary tract cancer statistics registry from 1998 to 2004 in Japan. J Hepatobiliary Pancreat Surg 2009, 16:1-7.
• [3]Sasaki T, Isayama H, Nakai Y, Koike K: Current status of chemotherapy for the treatment of advanced biliary tract cancer. Korean J Intern Med 2013, 28:515-524.
• [4]Sasaki T, Isayama H, Nakai Y, Ito Y, Kogure H, Togawa O, Toda N, Yasuda I, Hasebe O, Maetani I, Sasahira N, Hirano K, Tsujino T, Tada M, Omata M: Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 2010, 65:1101-1107.
• [5]Matsuda T, Shikata S, Minato H, Aikawa I: Two cases of advanced biliary tract cancer successfully treated with gemcitabine combination chemotherapy. Gan To Kagaku Ryoho 2008, 35:1779-1782.
• [6]Morimoto H, Ajiki T, Takase S, Fujita T, Matsumoto T, Mita Y, Matsumoto I, Fujino Y, Suzuki Y, Kuroda Y, Ku Y: Resection of gallbladder cancer with hepatic metastasis after chemotherapy with gemcitabine. J Hepatobiliary Pancreat Surg 2008, 15:655-658.
• [7]Kitajima K, Kobayashi S, Shiba H, Uwagawa T, Ishida Y, Aiba K, Kawakami M, Yanaga K: Successful treatment of advanced gallbladder cancer with an anticancer drug S-1: assessment based on intratumoral gene. Int J Clin Oncol 2008, 13:545-551.
• [8]Shirabe K, Tomoyuki A, Kiyoshi K, Akahoshi K: The survival impact of chemotherapy in the patient with gall bladder cancer - a pilot study. J Japan Biliary Assoc 2008, 22:41-46.
• [9]Hasegawa N, Abei M, Sasaki R, Pak S, Moriwaki T, Minami Y, Fukuda K, Hirai S, Shoda J, Ohkouchi N, Hyodo I: A case with Stage IVb advanced gallbladder cancer curatively resected following effective S-1 chemotherapy. J Japan Biliary Assoc 2010, 24:723-728.
• [10]Yoshida R, Matsuda T, Watanabe T, Iwadou H, Hunabiki K, Kamikawa Y: A case of gallbladder cancer which completely responded to gemcitabine. Gan To Kagaku Ryoho 2010, 37:1771-1773.
• [11]Takita M, Iwasaki E, Hatogai K, Kishino R, Seki E, Izumiya M, Maeda N, Nakazawa A, Mizuki A, Handa K, Shimoyama Y, Mukai K, Higuchi H, Takaishi H, Hibi T, Tsukada N: Advanced gallbladder cancer that showed complete response to gemcitabine plus S-1 chemotherapy. J Japanese Soc Gastroenterol 2011, 108:1263-1270.
• [12]Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010, 362:1273-1281.
• [13]Kanai M, Yoshimura K, Tsumura T, Asada M, Suzuki C, Niimi M, Matsumoto S, Nishimura T, Nitta T, Yasuchika K, Taura K, Mori Y, Hamada A, Inoue N, Tada S, Yanagihara K, Yazumi S, Osaki Y, Chiba T, Ikai I, Fukushima M, Uemoto S, Hatano E: A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 2011, 67:1429-1434.
• [14]Morizane C, Okusaka T, Mizusawa J, Takashima A, Ueno M, Ikeda M, Hamamoto Y, Ishii H, Boku N, Furuse J: Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805). Cancer Sci 2013, 104:1211-1216.
• [15]Walter T, Horgan AM, McNamara M, McKeever L, Min T, Hedley D, Serra S, Krzyzanowska MK, Chen E, Mackay H, Feld R, Moore M, Knox JJ: Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: a large retrospective study. Eur J Cancer 2013, 49:329-335.
• [16]Lee MA: Gemcitabine and cisplatin combination chemotherapy in intrahepatic cholangiocarcinoma as second-line treatment: report of four cases. Jpn J Clin Oncol 2004, 34:547-550.
• [17]Sasaki T, Isayama H, Nakai Y, Mizuno S, Yamamoto K, Yagioka H, Yashima Y, Kawakubo K, Kogure H, Togawa O, Matsubara S, Sasahira N, Hirano K, Tsujino T, Tada M, Omata M, Koike K: Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancer. Invest New Drugs 2011, 29:1488-1493.
• [18]Paule B, Herelle M-O, Rage E, Ducreux M, Adam R, Guettier C, Bralet M-P: Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas. Oncology 2007, 72:105-110.
• [19]Oh SY, Jeong CY, Hong SC, Kim TH, Ha CY, Kim HJ, Lee G-W, Hwang IG, Jang JS, Kwon H-C, Kang JH: Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness. Invest New Drugs 2011, 29:1066-1072.
• [20]Suzuki E, Ikeda M, Okusaka T, Nakamori S, Ohkawa S, Nagakawa T, Boku N, Yanagimoto H, Sato T, Furuse J: A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer. Cancer Chemother Pharmacol 2013, 71:1141-1146.
• [21]Sasaki T, Isayama H, Nakai Y, Mizuno S, Yamamoto K, Yagioka H, Yashima Y, Kawakubo K, Kogure H, Togawa O, Matsubara S, Ito Y, Sasahira N, Hirano K, Tsujino T, Toda N, Tada M, Omata M, Koike K: Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine. Invest New Drugs 2012, 30:708-713.
• [22]Lim K-H, Han S-W, Oh D-Y, Im S-A, Kim T-Y, Bang Y-J: Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer. Oncology 2012, 83:57-66.
• [23]Roth A, Schleyer E, Schoppmeyer K, Kluge R, Wittekind C, Mössner J, Wiedmann M: Imatinib mesylate for palliative second-line treatment of advanced biliary tract cancer: a bicentric phase II study. Onkologie 2011, 34:469-470.
• [24]Yi JH, Thongprasert S, Lee J, Doval DC, Park SH, Park JO, Park YS, Kang WK, Lim HY: A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: a multicentre, multinational study. Eur J Cancer 2012, 48:196-201.